Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis
- Angew Chem Int Ed Engl. 2016 Sep 5;55(37):11193-11197. doi: 10.1002/anie.201603746.
- 1. Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy.
- 2. Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, CA 92697-4625, USA.
- 3. Anteana Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego CA 92121, USA.
- # Contributed equally.
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation. Their actions are terminated by the intracellular cysteine amidase, N-acylethanolamine acid amidase (NAAA). Even though NAAA may offer a new target for anti-inflammatory therapy, the lipid-like structures and reactive warheads of current NAAA inhibitors limit the use of these agents as oral drugs. A series of novel benzothiazole-piperazine derivatives that inhibit NAAA in a potent and selective manner by a non-covalent mechanism are described. A prototype member of this class (8) displays high oral bioavailability, access to the central nervous system (CNS), and strong activity in a mouse model of Multiple Sclerosis (MS). This compound exemplifies a second generation of non-covalent NAAA inhibitors that may be useful in the treatment of MS and other chronic CNS disorders.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Ceramidase